Combinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells

Sep 28, 2026

Uploaded by Muffet

The Myc gene is a key oncogene in triple-negative breast cancer (TNBC). This study evaluates synergistic anticancer effects by combining Myc decoy oligodeoxynucleotides-encapsulated niosomes-selenium hybrid nanocarriers with X-irradiation on the MDA-MB-468 breast cancer cell line. Myc decoy and scramble ODNs were designed from Bcl2 promoter sequences and loaded into chitosan to form Chi-Se-DEC, then encapsulated in niosome-nanocarriers (NISM@Chi-Se-DEC).

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages15

Reading Time38 min

AccessFree to download

Key findings

Experimental design and cell model

Nanocarrier characterization

Cellular assays and combined treatment

ONCOLOGY RESEARCH 2024 32(2): 309-323 Combinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells BEHROOZ JOHARI 1,2,\#,*; MILAD PARVINZAD LEILAN 1,\#; MAHMOUD GHARBAVI3; YOUSEF MORTAZAVI 1; ALI SHARAFI2; HAMED REZAEEJAM4 1 Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran 2 Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran 3 Nanotechnology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 4 Department of Radiology Technology, School of Allied Medical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran Key words: Combinational therapy, Antisense therapy, Myc signaling pathway, Niosomes, Radiation therapy, SeNPs Abstract: The Myc gene is the essential oncogene in triple-negative breast cancer (TNBC) . This study investigates the synergistic effects of combining Myc decoy oligodeoxynucleotides-encapsulated niosomes-selenium hybrid nanocarriers with X-irradiation exposure on the MDA-MB-468 cell line. Decoy and scramble ODNs for Myc transcription factor were designed and synthesized based on promoter sequences of the Bcl2 gene. The nanocarriers were synthesized by loading Myc ODNs and selenium into chitosan (Chi-Se-DEC), which was then encapsulated in niosome-nanocarriers (NISM@Chi-Se-DEC) . FT-IR, DLS, FESEM, and hemolysis tests were applied to conﬁrm its characterization and physicochemical properties. Moreover, cellular uptake, cellular toxicity, apoptosis, cell cycle, and scratch repair assays were performed to evaluate its anticancer effects on cancer cells. All anticancer assessments were repeated under X-ray irradiation conditions (fractionated 2Gy) . Physicochemical characteristics of niosomes containing SeNPs and ODNs showed that it is synthesized appropriately. It revealed that the anticancer effect of NISM@Chi-Se-DEC can be signiﬁcantly improved in combination with X-ray irradiation treatment. It can be concluded that NISM@Chi-Se-DEC nanocarriers have the potential as a therapeutic agent for cancer treatment, particularly in combination with radiation therapy and in-vivo experiments are necessary to conﬁrm the efﬁcacy of this nano-drug. List of Abbreviations SeNPs Selenium nanoparticles BSA Bovine serum albumin Chi Chitosan BC Breast cancer BCSCs Breast cancer stem cells TNBC Triple-negative breast cancer EDC 1-(3-dimethylaminopropyl)-3-ethylcarbodii mide hydrochloride NHS N-hydroxysuccinimide Cy3 Cyanine-3 *Address correspondence to: Behrooz Johari, [Behroozjohari@yahoo.com](Behroozjohari@yahoo.com), [Dr.johari@zums.ac.ir](Dr.johari@zums.ac.ir) \#Behrooz Johari and Milad Parvinzad Leilan contributed equally to this work and hence are co-ﬁrst authors Received: 06 July 2023; Accepted: 13 October 2023; Published: 28 December 2023 Se Selenium ODNs Oligodeoxynucleotides SCR Scrambled TFD Transcription factor decoy PS Phosphorothioate PDI Polydispersity Index DLS Dynamic light scattering FT-IR Fourier transform infrared TEM Transmission electron microscope SDS Sodium dodecyl sulfate PI Propidium iodide Introduction Triple-negative breast cancer is a subtype of breast cancer where cancer cells lack the human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and Doi: [10.32604/or.2023.043576 www.techscience.com/journal/or](10.32604/or.2023.043576 www.techscience.com/journal/or) This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 310 BEHROOZ JOHARI et al. progesterone receptor (PR) [1,2] . The treatment of TNBC is challenging because these cells are very invasive and cause early metastasis [3] . Common approaches to treating breast cancer include surgery, hormo

FAQs

What is the main therapeutic strategy tested in this study?

The study tests a combinational approach pairing Myc decoy oligodeoxynucleotides-encapsulated hybrid nanocarriers with X-irradiation for improved anticancer effects.

Which breast cancer cell line was used?

The experiments were performed on the MDA-MB-468 cell line.

How was the nanocarrier constructed and characterized?

Myc ODNs and selenium were loaded into chitosan (Chi-Se-DEC) and encapsulated into niosomes (NISM@Chi-Se-DEC). FT-IR, DLS, FESEM, and hemolysis tests were used to confirm characterization and physicochemical properties.

Sep 28, 2026

Uploaded by Muffet